Evidence map›Paper›PMID 31419957›Full record

ArticleBMC cancer2019

The peroxidase PRDX1 inhibits the activated phenotype in mammary fibroblasts through regulating c-Jun N-terminal kinases.

Agnieszka Jezierska-Drutel, Shireen Attaran, Barbara L Hopkins, John J Skoko, Steven A Rosenzweig, Carola A Neumann

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Regulation of ROS signaling by TIGAR induces cancer-modulating responses in the tumor microenvironment.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. PRDX1 is essential for the viability and maintenance of reactive oxygen species in chicken DT40.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021
    Article
  12. Knockout Mouse Models for Peroxiredoxins.Antioxidants (Basel, Switzerland) · 2020
    Review
  13. Silencing RPL9 promotes malignant proliferation in breast cancer cells.International journal of immunopathology and pharmacology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Agnieszka Jezierska-DrutelDepartment of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Shireen AttaranDepartment of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Barbara L HopkinsDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
John J SkokoDepartment of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Steven A RosenzweigDepartment of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, 29425, USA.
Carola A NeumannDepartment of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. neumannc@upmc.edu.
University of Pittsburgh · USCancer Research Center · USMedical University of South Carolina · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
The Role of Peroxiredoxin1 & Reactive Oxygen Species in Breast Tumor InitiationR01CA131350 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEUMANN, CAROLA ANKE · 2010 to 2014
$1.5M
INHIBITION OF IGF MEDIATED TUMORIGENESISR01CA078887 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ROSENZWEIG, STEVEN A. · 2000 to 2004
$1.4M
NCI NIH HHS P30 CA047904NCI NIH HHS P30CA047904NCI NIH HHS R01 CA078887NCI NIH HHS R01 CA131350
6 · The paper itself

Abstract

backgroundReactive oxygen species (ROS), including hydrogen peroxide, drive differentiation of normal fibroblasts into activated fibroblasts, which can generate high amounts of hydrogen peroxide themselves, thereby increasing oxidative stress in the microenvironment. This way, activated fibroblasts can transition into cancer-associated fibroblasts (CAFs).

methodsMammary fibroblasts from either female 8 weeks old PRDX1 knockout and wildtype mice or Balb/c mice were studied for characteristic protein expression using immunofluorescence and immunoblotting. Cancer-associated fibroblasts was examined by transwell migration and invasion assays. The binding of PRDX1 to JNK1 was assessed by co-immuneprecipitation and JNK regulation of CAF phenotypes was examined using the JNK inhibitor SP600125. Extracellular hydrogen peroxide levels were measured by chemiluminescence via the reaction between hypochlorite and luminol. Statistical analyses were done using Students t-test.

resultsWe show here PRDX1 activity as an essential switch in regulating the activated phenotype as loss of PRDX1 results in the development of a CAF-like phenotype in mammary fibroblasts. We also show that PRDX1 regulates JNK kinase signaling thereby inhibiting CAF-like markers and CAF invasion. Inhibition of JNK activity reduced these behaviors.

conclusionsThese data suggest that PRDX1 repressed the activated phenotype of fibroblasts in part through JNK inhibition which may present a novel therapeutic option for CAF-enriched cancers such as breast cancer.

Indexed as

PhenotypeActinsAnimalsAnthracenesFemaleFibroblastsGene Knockout TechniquesHEK293 CellsHumansHydrogen PeroxideMammary Glands, AnimalMiceMice, Inbred BALB CMitogen-Activated Protein Kinase 8Oxidative StressPeroxiredoxinsActinsalpha-smooth muscle actin, mouseAnthracenesHydrogen PeroxideMitogen-Activated Protein Kinase 8PeroxiredoxinsPRDX1 protein, humanPrdx1 protein, mousepyrazolanthroneReactive Oxygen SpeciesBreast cancerBreast tumorigenesisCancer-associated fibroblastsHydrogen peroxideJNKMammary fibroblastsperoxiredoxin1

Identifiers

PMID31419957
PMCPMC6697950
OpenAlexW2967167198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.